ArticleScientific reports2024
Synergistic chemo-photothermal therapy using gold nanorods supported on thiol-functionalized mesoporous silica for lung cancer treatment.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- Lung cancer therapy using a chitosan-based nano drug discovery system of silver nanoparticles and chemotherapeutics.Discover oncology · 2026Article
- Mesoporous silica nanoparticles functionalized with folic acid and zinc for enhanced targeted delivery of daunorubicin to breast cancer cells.Scientific reports · 2026Article
- Resonance Energy Transfer-Driven Photothermal Nanoagent Enables Melanoma Ablation Under Low-Power Near-Infrared Irradiation.Advanced functional materials · 2026Article
- Hydrogel-mediated tri-modal nanoplatform for localized colorectal cancer therapy via smart chemo-photothermal-radiotherapy.Journal of biological engineering · 2026Article
- Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer.International journal of nanomedicine · 2026Review
- Gold Nanoparticles in Biomedical Applications: Synthesis, Functionalization, and Recent Advances.Molecules (Basel, Switzerland) · 2025Review
- Synergistic chemo-photothermal therapy using doxorubicin-loaded gold nanorods for enhanced apoptosis in lung cancer cells.Scientific reports · 2025Article
- Silica Aerogels in Nano Drug Delivery Systems: A Comprehensive Review from Preparation to Medical Applications.Gels (Basel, Switzerland) · 2025Review
- Conjugation of hydrazine to PEGylated silica-coated magnetite nanoparticles as pH-responsive magnetic nanocarriers for covalent loading and controlled release of doxorubicin.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Surface Functionalization of Nanoparticles for Enhanced Electrostatic Adsorption of Biomolecules.Molecules (Basel, Switzerland) · 2025Review
- Protein-functionalized and intrinsically radiolabeled [European journal of nuclear medicine and molecular imaging · 2025Article
- Synergistic Cancer Therapies Enhanced by Nanoparticles: Advancing Nanomedicine Through Multimodal Strategies.Pharmaceutics · 2025Review
- Mechanistic insights and therapeutic strategies for targeting autophagy in pancreatic ductal adenocarcinoma.Discover oncology · 2025Review
- Controlled electrochemical fabrication of large and stable gold nanorods with reduced cytotoxicity.Scientific reports · 2025Article
- Advances in controlled release drug delivery systems based on nanomaterials in lung cancer therapy: A review.Medicine · 2025Review
- In vivo Targeted Delivery of Extracellular Vesicle‒Gold Nanorod Hybrids to Metastatic Melanoma Lung Tumors.International journal of nanomedicine · 2025Article
- Advancements in Nano-Delivery Systems for Photodynamic and Photothermal Therapy to Induce Immunogenic Cell Death in Tumor Immunotherapy.International journal of nanomedicine · 2025Review
- Graphene Oxide Nanoparticles for Photothermal Treatment of Hepatocellular Carcinoma Using Low-Intensity Femtosecond Laser Irradiation.Molecules (Basel, Switzerland) · 2024Article
- Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management.Nanomedicine (London, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapy necessitates the development of novel and effective treatment modalities to combat the complexity of this disease. In this project, we propose a synergistic approach by combining chemo-photothermal treatment using gold nanorods (AuNRs) supported on thiol-functionalized mesoporous silica, offering a promising solution for enhanced lung cancer therapy. To begin, mesoporous MCM-41 was synthesized using a surfactant-templated sol-gel method, chosen for its desirable porous structure, excellent biocompatibility, and non-toxic properties. Further, thiol-functionalized MCM-41 was achieved through a simple grafting process, enabling the subsequent synthesis of AuNRs supported on thiol-functionalized MCM-41 (AuNR@S-MCM-41) via a gold-thiol interaction. The nanocomposite was then loaded with the anticancer drug doxorubicin (DOX), resulting in AuNR@S-MCM-41-DOX. Remarkably, the nanocomposite exhibited pH/NIR dual-responsive drug release behaviors, facilitating targeted drug delivery. In addition, it demonstrated exceptional biocompatibility and efficient internalization into A549 lung cancer cells. Notably, the combined photothermal-chemo therapy by AuNR@S-MCM-41-DOX exhibited superior efficacy in killing cancer cells compared to single chemo- or photothermal therapies. This study showcases the potential of the AuNR@S-MCM-41-DOX nanocomposite as a promising candidate for combined chemo-photothermal therapy in lung cancer treatment. The innovative integration of gold nanorods, thiol-functionalized mesoporous silica, and pH/NIR dual-responsive drug release provides a comprehensive and effective therapeutic approach for improved outcomes in lung cancer therapy. Future advancements based on this strategy hold promise for addressing the challenges posed by cancer and transforming patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.